Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2916190 | 1.00 | MEN1 (0.41) | MEN1KMT2ANPSR1PKMNR1D1 | |
| SCHEMBL13613626 | 1.00 | MEN1 (0.41) | MEN1KMT2ANPSR1PKMNR1D1 | |
| SCHEMBL2914820 | 0.90 | MEN1 (0.40) | MEN1KMT2ANPSR1PKMHCRTR2 | |
| SCHEMBL3074571 | 0.86 | NR1H2 (0.41) | MEN1KMT2ANR1H2 | |
| SCHEMBL3089693 | 0.86 | NR1H2 (0.41) | MEN1KMT2ANR1H2 | |
| SCHEMBL3079034 | 0.86 | NR1H2 (0.41) | MEN1KMT2ANR1H2 | |
| SCHEMBL3079834 | 0.86 | NR1H2 (0.41) | MEN1KMT2ANR1H2 | |
| SCHEMBL8224134 | 0.86 | NR1H2 (0.41) | MEN1KMT2ANR1H2 | |
| SCHEMBL3074566 | 0.86 | NR1H2 (0.41) | MEN1KMT2ANR1H2 | |
| SCHEMBL11355508 | 0.86 | NR1H2 (0.41) | MEN1KMT2ANR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856096-B1 | PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2010-09-01 | — | — | EP | disclosed |
| US-7622585-B2 | Phenylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1856096-A2 | PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | Bristol-Myers Squibb Company (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060166997-A1 | Phenylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| WO-2006076246-A2 | PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166997-A1 | Phenylglycinamide derivatives useful as anticoagulants | TFPI, SERPINC1, SERPINE1 | MEN1 2580/4885KMT2A 860/4885NPSR1 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.